ST未名：预计2025年净亏损5500万元-9000万元

Core Viewpoint - ST Unimed (002581.SZ) forecasts a significant loss for the fiscal year 2025, with expected revenue between 355 million to 398 million yuan and a net loss attributable to shareholders ranging from 55 million to 90 million yuan, compared to a loss of 137 million yuan in the same period last year [1] Financial Performance - The company anticipates a revenue of 355 million to 398 million yuan for the reporting period [1] - The net loss attributable to shareholders is projected to be between 55 million to 90 million yuan, an improvement from the previous year's loss of 137 million yuan [1] - The net profit after excluding non-recurring gains and losses is expected to be a loss of 70 million to 105 million yuan, compared to a loss of 111 million yuan in the same period last year [1] Operational Challenges - The primary reason for the company's losses is the suspension of production and sales by its subsidiary, Tianjin Unimed Biopharmaceutical Co., Ltd., which has adversely affected related business revenue [1] - The company is actively working on rectification to expedite the resumption of production, but ongoing costs and expenses continue to contribute to the losses [1]